|
Synonyms: DNIB0600A | RG-7599 | RG7599
Compound class:
Antibody
Comment: Lifastuzumab vedotin is an antibody drug conjugate containing an anti-SLC34A2 (sodium phosphate 2 transporter) monoclonal antibody linked to the toxin monomethyl auristatin E (MMAE, aka vedotin; PubChem CID 11542188).
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record. Peptide sequence match identifies US8535675 as the covering patent [2], and also identifies the target antigen denoted as TAT211 in this patent as the sodium phosphate transporter. |
| References |
|
1. Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I et al.. (2018)
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol, 29 (4): 917-923. [PMID:29401246] |
|
2. Dennis M, Rubinfeld B, Polakis P. (2013)
Compositions and methods for the diagnosis and treatment of tumor. Patent number: US8535675 B2. Assignee: Genentech, Inc.. Priority date: 30/11/2009. Publication date: 17/09/2013. |
